NCT04912765 — National Cancer Centre, Singapore neoantigen vaccine trial
Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC
Registry record
| Registry ID | NCT04912765 ↗ |
|---|---|
| Lead sponsor | National Cancer Centre, Singapore |
| Collaborators | Bristol-Myers Squibb |
| Phase | Phase 2 |
| Status | Recruiting |
| Indication | Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer, Colorectal Carcinoma, Liver Metastases |
| Enrollment | 60 participants (target) |
| Start date | 2021-04-15 |
| Primary completion | 2026-12 (est.) |
| Last registry update | 31 Jul 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT04912765), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT04912765?
NCT04912765 (Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC) is registered on ClinicalTrials.gov as Phase 2, sponsored by National Cancer Centre, Singapore.
Is NCT04912765 recruiting?
As of the 2026-07-31 registry update, NCT04912765 is listed as "Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT04912765?
The lead sponsor is National Cancer Centre, Singapore. Collaborators: Bristol-Myers Squibb.
What condition does NCT04912765 study?
The registered conditions are Hepatocellular Carcinoma, Hepatocellular Cancer, Colorectal Cancer, Colorectal Carcinoma, Liver Metastases. Primary completion is listed as 2026-12 (estimated).
Are results available for NCT04912765?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT04912765.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.